Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gordon C Jayson

Showing results (111-120 of 126) with videos related to

Pageof 13
Sort By:
Lancet (London, England)|March 31, 2016
Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trialJonathan A Ledermann, Andrew C Embleton, Fharat Raja, et al.
British Journal of Cancer|April 8, 2026
Phase Ib trial of SL-172154, a bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, in combination with mirvetuximab soravtansine or pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancerYvette Drew, Lucy Gilbert, Alejandro Martinez Bueno, et al.
International Journal of Radiation Oncology, Biology, Physics|March 31, 2009
Preliminary study of oxygen-enhanced longitudinal relaxation in MRI: a potential novel biomarker of oxygenation changes in solid tumorsJames P B O'Connor, Josephine H Naish, Geoff J M Parker, et al.
Nature Communications|February 15, 2020
A living biobank of ovarian cancer ex vivo models reveals profound mitotic heterogeneityLouisa Nelson, Anthony Tighe, Anya Golder, et al.
European Journal of Human Genetics : EJHG|July 12, 2020
Mainstreaming germline BRCA1/2 testing in non-mucinous epithelial ovarian cancer in the North West of EnglandNicola Flaum, Robert D Morgan, George J Burghel, et al.
Cancer Chemotherapy and Pharmacology|October 22, 2013
A phase 1 trial of intravenous 4-(N-(S-glutathionylacetyl)amino) phenylarsenoxide (GSAO) in patients with advanced solid tumoursLaura Horsley, Jeff Cummings, Mark Middleton, et al.
The Lancet. Oncology|December 28, 2020
Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trialRobert D Morgan, Iain A McNeish, Adrian D Cook, et al.
The Lancet. Oncology|June 28, 2015
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trialAmit M Oza, Adrian D Cook, Jacobus Pfisterer, et al.
Nature Communications|November 9, 2018
Plasma Tie2 is a tumor vascular response biomarker for VEGF inhibitors in metastatic colorectal cancerGordon C Jayson, Cong Zhou, Alison Backen, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 18, 2023
Homologous recombination deficiency in newly diagnosed FIGO stage III/IV high-grade epithelial ovarian cancer: a multi-national observational studyRobert D Morgan, Andrew R Clamp, Bethany M Barnes, et al.
Pageof 13

Showing results (111-120 of 126) with videos related to

Sort By:
Pageof 13
Lancet (London, England)|March 31, 2016
Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trialJonathan A Ledermann, Andrew C Embleton, Fharat Raja, et al.
British Journal of Cancer|April 8, 2026
Phase Ib trial of SL-172154, a bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, in combination with mirvetuximab soravtansine or pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancerYvette Drew, Lucy Gilbert, Alejandro Martinez Bueno, et al.
International Journal of Radiation Oncology, Biology, Physics|March 31, 2009
Preliminary study of oxygen-enhanced longitudinal relaxation in MRI: a potential novel biomarker of oxygenation changes in solid tumorsJames P B O'Connor, Josephine H Naish, Geoff J M Parker, et al.
Nature Communications|February 15, 2020
A living biobank of ovarian cancer ex vivo models reveals profound mitotic heterogeneityLouisa Nelson, Anthony Tighe, Anya Golder, et al.
European Journal of Human Genetics : EJHG|July 12, 2020
Mainstreaming germline BRCA1/2 testing in non-mucinous epithelial ovarian cancer in the North West of EnglandNicola Flaum, Robert D Morgan, George J Burghel, et al.
Cancer Chemotherapy and Pharmacology|October 22, 2013
A phase 1 trial of intravenous 4-(N-(S-glutathionylacetyl)amino) phenylarsenoxide (GSAO) in patients with advanced solid tumoursLaura Horsley, Jeff Cummings, Mark Middleton, et al.
The Lancet. Oncology|December 28, 2020
Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trialRobert D Morgan, Iain A McNeish, Adrian D Cook, et al.
The Lancet. Oncology|June 28, 2015
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trialAmit M Oza, Adrian D Cook, Jacobus Pfisterer, et al.
Nature Communications|November 9, 2018
Plasma Tie2 is a tumor vascular response biomarker for VEGF inhibitors in metastatic colorectal cancerGordon C Jayson, Cong Zhou, Alison Backen, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 18, 2023
Homologous recombination deficiency in newly diagnosed FIGO stage III/IV high-grade epithelial ovarian cancer: a multi-national observational studyRobert D Morgan, Andrew R Clamp, Bethany M Barnes, et al.
Pageof 13